eligibility_summary
Eligible: consenting healthy men/women 18–55, BMI 18–32, weight 50–110 kg, normal history/physical/vitals/ECG/labs. Exclude: males with partners pregnant/lactating/planning pregnancy during study or 90 days post-dose, recent investigational drug/device (within 30 days or 5 half-lives), diseases posing unacceptable risk, significant drug/food allergies (e.g., anaphylaxis, hepatotoxicity, steroid/epinephrine or ED treatment).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: ALTB-268 (biologic, monoclonal antibody) vs placebo (buffer), given subcutaneously in single- and multiple-ascending doses to healthy volunteers. Mechanism of action: ALTB-268 is designed as an immune-checkpoint agonist antibody to PSGL-1 (P-selectin glycoprotein ligand-1). By agonizing PSGL-1 on T cells, it selectively attenuates or eliminates chronically activated effector/memory T cells via activation-induced cell death and dampening of TCR-driven signaling, while largely sparing resting/naïve T cells. Target cells/pathways: PSGL-1-expressing T cells (including pathogenic Th1/Th17 and cytotoxic T cells), downstream T-cell activation pathways and proinflammatory cytokine production are expected to be reduced. Comparator has no pharmacologic activity.